Tags

Type your tag names separated by a space and hit enter

c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Cancer Chemother Pharmacol. 2002 Aug; 50(2):167-9.CC

Abstract

PURPOSE

In order to determine whether Ewing tumour patients may be potential candidates for imatinib mesylate therapy, we analysed the expression of the currently known imatinib mesylate-sensitive tyrosine kinases and tested sensitivity to imatinib mesylate in a panel of eight Ewing tumour cell lines in vitro.

METHODS

Expression of the different tyrosine kinases was assessed by flow cytometry and RT-PCR. Sensitivity to imatinib mesylate was analysed using a standard MTT proliferation assay.

RESULTS

Flow cytometric and RT-PCR analyses in a panel of eight Ewing tumour cell lines demonstrated expression of several imatinib mesylate-sensitive tyrosine kinases, including c-KIT, platelet-derived growth factor receptor, c-ABL and c-ARG. However, in the MTT proliferation assay, all eight Ewing tumour cell lines were found to be resistant to imatinib mesylate at concentrations ranging from 0.1 to 10 micro M.

CONCLUSIONS

Despite the expression of imatinib mesylate-sensitive tyrosine kinases, Ewing tumour cells proved resistant to imatinib mesylate in vitro. This observation has implications for the selection of patients for experimental therapy with imatinib mesylate.

Authors+Show Affiliations

University Children's Hospital Muenster, Department of Pediatric Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, 48129 Muenster, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12172985

Citation

Hotfilder, Marc, et al. "C-KIT-expressing Ewing Tumour Cells Are Insensitive to Imatinib Mesylate (STI571)." Cancer Chemotherapy and Pharmacology, vol. 50, no. 2, 2002, pp. 167-9.
Hotfilder M, Lanvers C, Jürgens H, et al. C-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother Pharmacol. 2002;50(2):167-9.
Hotfilder, M., Lanvers, C., Jürgens, H., Boos, J., & Vormoor, J. (2002). C-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemotherapy and Pharmacology, 50(2), 167-9.
Hotfilder M, et al. C-KIT-expressing Ewing Tumour Cells Are Insensitive to Imatinib Mesylate (STI571). Cancer Chemother Pharmacol. 2002;50(2):167-9. PubMed PMID: 12172985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). AU - Hotfilder,Marc, AU - Lanvers,Claudia, AU - Jürgens,Heribert, AU - Boos,Joachim, AU - Vormoor,Josef, Y1 - 2002/06/15/ PY - 2002/01/02/received PY - 2002/05/03/accepted PY - 2002/8/13/pubmed PY - 2002/10/9/medline PY - 2002/8/13/entrez SP - 167 EP - 9 JF - Cancer chemotherapy and pharmacology JO - Cancer Chemother. Pharmacol. VL - 50 IS - 2 N2 - PURPOSE: In order to determine whether Ewing tumour patients may be potential candidates for imatinib mesylate therapy, we analysed the expression of the currently known imatinib mesylate-sensitive tyrosine kinases and tested sensitivity to imatinib mesylate in a panel of eight Ewing tumour cell lines in vitro. METHODS: Expression of the different tyrosine kinases was assessed by flow cytometry and RT-PCR. Sensitivity to imatinib mesylate was analysed using a standard MTT proliferation assay. RESULTS: Flow cytometric and RT-PCR analyses in a panel of eight Ewing tumour cell lines demonstrated expression of several imatinib mesylate-sensitive tyrosine kinases, including c-KIT, platelet-derived growth factor receptor, c-ABL and c-ARG. However, in the MTT proliferation assay, all eight Ewing tumour cell lines were found to be resistant to imatinib mesylate at concentrations ranging from 0.1 to 10 micro M. CONCLUSIONS: Despite the expression of imatinib mesylate-sensitive tyrosine kinases, Ewing tumour cells proved resistant to imatinib mesylate in vitro. This observation has implications for the selection of patients for experimental therapy with imatinib mesylate. SN - 0344-5704 UR - https://www.unboundmedicine.com/medline/citation/12172985/c_KIT_expressing_Ewing_tumour_cells_are_insensitive_to_imatinib_mesylate__STI571__ L2 - https://dx.doi.org/10.1007/s00280-002-0477-8 DB - PRIME DP - Unbound Medicine ER -